文献速递产科母胎医学

阴道单硝酸异山梨酯辅助引产用于妊娠期高血压疾病:随机对照试验

Addition of vaginal isosorbide mononitrate for labor induction in pregnancies complicated by hypertensive diseases of pregnancy: a randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2021-02-27

结果显示两组剖宫产率无差异(32.6% vs 25.3%),用药组头痛增加,安慰剂组临床绒毛膜羊膜炎增加。

要点

  • 加用阴道单硝酸异山梨酯未降低妊娠期高血压疾病引产的剖宫产率。
  • 用药组头痛发生率高于安慰剂组(42.7% vs 31%)。
  • 安慰剂组临床绒毛膜羊膜炎发生率高于用药组(8% vs 0%)。

核心结论

  • 在妊娠期高血压疾病引产孕妇中,加用阴道单硝酸异山梨酯未能减少剖宫产。

研究设计与样本

  • 89例随机至单硝酸异山梨酯组,87例随机至安慰剂组,在米索前列醇基础上最多加用3剂40mg阴道单硝酸异山梨酯。

主要发现

  • 剖宫产率两组相似(32.6% vs 25.3%;相对风险1.29;95%CI 0.81-2.06;P=.39)。
  • 产妇头痛在单硝酸异山梨酯组增加(42.7% vs 31%;相对风险1.52;95%CI 1.04-2.23;P=.04)。
  • 临床绒毛膜羊膜炎在安慰剂组增加(0% vs 8%;P=.02)。
  • 次要结局两组相似。

关键数值与推荐

  • 剖宫产率:单硝酸异山梨酯组32.6%,安慰剂组25.3%(RR 1.29;95%CI 0.81-2.06;P=.39)。
  • 产妇头痛:单硝酸异山梨酯组42.7%,安慰剂组31%(RR 1.52;95%CI 1.04-2.23;P=.04)。
  • 临床绒毛膜羊膜炎:单硝酸异山梨膜炎组0%,安慰剂组8%(P=.02)。

临床怎么用

  • 对妊娠期高血压疾病引产孕妇,不应常规加用阴道单硝酸异山梨酯以降低剖宫产率。
  • 加用该药需权衡头痛风险,并注意安慰剂组绒毛膜羊膜炎信号。

局限性

  • 引产管理按提供者偏好进行,未标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnancies complicated by hypertensive disease of pregnancy often require labor induction. Rates of cesarean delivery range from 15% to 60% in this population. Nitric oxide deficiency has been shown to underlay the pathophysiology of preeclampsia, and nitric oxide promotes cervical ripening. OBJECTIVE: We hypothesized that addition of vaginal isosorbide mononitrate for labor induction could decrease the rate of cesarean delivery in pregnancies with hypertensive disease of pregnancy. STUDY DESIGN: This study was a double-blind, placebo-controlled, randomized trial of patients with singleton pregnancy at ≥24 weeks' gestation undergoing labor induction for hypertensive diseases of pregnancy between November 2017 and February 2020. Participants were eligible if their Bishop score was <6 and if their cervical dilation was ≤2 cm. In addition, participants received up to 3 doses of 40 mg isosorbide mononitrate in addition to misoprostol for labor induction. Labor management was per healthcare provider preference. The primary outcome was rate of cesarean delivery. Secondary outcomes included the length of labor and frequency of intrapartum adverse events, including the use of intrapartum antihypertensive agents. RESULTS: 89 women were randomized to the isosorbide mononitrate group, and 87 women were randomized to the placebo group. Cesarean delivery rates were similar in both groups (32.6% vs 25.3%; relative risk, 1.29; 95% confidence interval, 0.81-2.06; P=.39). Maternal headache was increased in patients exposed to isosorbide mononitrate (42.7% vs 31%; relative risk, 1.52; 95% confidence interval, 1.04-2.23; P=.04). Clinical chorioamnionitis was increased in the placebo group (0% vs 8%; P=.02). Secondary outcomes were similar between groups. CONCLUSION: The addition of vaginal isosorbide mononitrate for labor induction in pregnancies complicated by hypertensive disease of pregnancy did not result in fewer cesarean deliveries.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Gee SE, Ma'ayeh M, Cackovic H, et al. Addition of vaginal isosorbide mononitrate for labor induction in pregnancies complicated by hypertensive diseases of pregnancy: a randomized controlled trial. Am J Obstet Gynecol MFM. 2021. PMID: 33652160. doi:10.1016/j.ajogmf.2021.100343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。